NCT06199037 is a Phase 2 clinical trial investigating SHR-1707, a novel bispecific antibody targeting both IL-17 and PD-1, in patients with Alzheimer's disease. The trial is sponsored by Shanghai Hengrui Pharmaceutical and is currently recruiting participants.
SHR-1707 represents an innovative approach to treating Alzheimer's disease by simultaneously modulating two key immune checkpoint pathways—IL-17 signaling and PD-1 signaling—potentially addressing the neuroinflammation that contributes to disease progression.
Trial Details
...
Overview
Mermaid diagram (expand to render)
NCT06199037 is a Phase 2 clinical trial investigating SHR-1707, a novel bispecific antibody targeting both IL-17 and PD-1, in patients with Alzheimer's disease. The trial is sponsored by Shanghai Hengrui Pharmaceutical and is currently recruiting participants.
SHR-1707 represents an innovative approach to treating Alzheimer's disease by simultaneously modulating two key immune checkpoint pathways—IL-17 signaling and PD-1 signaling—potentially addressing the neuroinflammation that contributes to disease progression.
Trial Details
| Parameter | Value | |-----------|-------| | NCT Number | NCT06199037 | | Phase | Phase 2 | | Status | Recruiting | | Enrollment | 45 participants | | Sponsor | Shanghai Hengrui Pharmaceutical | | Intervention | SHR-1707 (bispecific antibody) | | Study Type | Interventional |
Background
Bispecific Antibody Mechanism
SHR-1707 is a bispecific antibody engineered to bind to two distinct targets:
IL-17 (Interleukin-17): A pro-inflammatory cytokine implicated in chronic neuroinflammation
IL-17 is produced by Th17 cells and contributes to inflammatory responses
Elevated IL-17 levels have been associated with neurodegenerative processes
Blocking IL-17 signaling reduces neuroinflammation in preclinical models
PD-1 (Programmed Cell Death Protein 1): An immune checkpoint receptor
PD-1 negatively regulates T-cell activity and immune responses
PD-1 signaling can suppress anti-inflammatory responses
Modulating PD-1 can enhance immune surveillance and clearance
Rationale for AD
The dual-targeting approach of SHR-1707 addresses multiple aspects of neuroinflammation in Alzheimer's disease:
Chronic neuroinflammation: IL-17 promotes pro-inflammatory cytokine release from microglia
Immune checkpoint modulation: PD-1 modulation may enhance neuroprotective immune responses
Synergistic effect: Simultaneous IL-17 and PD-1 modulation may provide greater anti-inflammatory effect than single-target approaches
Complementary pathways: Targeting both pathways addresses multiple inflammatory cascades
Preclinical Evidence
Research on IL-17 and PD-1 pathways in AD models has shown:
IL-17 receptor signaling contributes to microglial activation
PD-1 blockade can enhance amyloid clearance
Combined immune modulation shows promise in preclinical neurodegeneration models
Bispecific antibodies offer advantages over combination therapy with single-target agents
Study Design
The trial will evaluate the safety and efficacy of SHR-1707 in patients with mild-to-moderate Alzheimer's disease. Key endpoints likely include:
Cognitive function measures (ADAS-Cog, MMSE)
Biomarker assessments (amyloid PET, tau PET, CSF markers)
Safety and tolerability
Immunological markers
Brain volume changes (MRI)
Cross-Links
[Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)